Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
56M
-
Number of holders
-
242
-
Total 13F shares, excl. options
-
58.4M
-
Shares change
-
+1.94M
-
Total reported value, excl. options
-
$1.56B
-
Value change
-
+$37.8M
-
Put/Call ratio
-
0.27
-
Number of buys
-
115
-
Number of sells
-
-111
-
Price
-
$26.75
Significant Holders of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) as of Q2 2024
281 filings reported holding SUPN - SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share as of Q2 2024.
SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) has 242 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.4M shares
.
Largest 10 shareholders include BlackRock Inc. (10.4M shares), VANGUARD GROUP INC (6.14M shares), ARMISTICE CAPITAL, LLC (5.27M shares), DIMENSIONAL FUND ADVISORS LP (2.87M shares), MACQUARIE GROUP LTD (2.68M shares), STATE STREET CORP (2.16M shares), Polar Capital Holdings Plc (1.94M shares), Stephens Investment Management Group LLC (1.9M shares), RENAISSANCE TECHNOLOGIES LLC (1.69M shares), and LOOMIS SAYLES & CO L P (1.56M shares).
This table shows the top 242 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.